Data demonstrate efficacy of more flexible dose of regorafenib to relieve side-effects in mCRC patients
Medical oncologists administer anticancer drug regorafenib to try to improve overall survival in patients with metastatic colorectal cancer who have ceased to respond to standard therapy (known as refractory mCRC). However, ...
Jul 6, 2019
0
0
